Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.37 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.37 |
| ▸ | CHRNA6 | Q15825 | 2/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.36 |
| ▸ | JAK1 | P23458 | 6/20 | 0.36 |
| ▸ | JAK2 | O60674 | 3/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.36 |
| ▸ | JAK3 | P52333 | 3/20 | 0.35 |
| ▸ | TYK2 | P29597 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12683438 | 0.89 | IRAK4 (0.40) | IRAK4MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL16478695 | 0.89 | IRAK4 (0.40) | IRAK4MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL12424315 | 0.86 | ALDH1A1 (0.39) | IRAK4MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL12683417 | 0.82 | MEN1 (0.41) | IRAK4MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL12683459 | 0.82 | MEN1 (0.41) | IRAK4MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL15014577 | 0.82 | ALDH1A1 (0.41) | MEN1ALDH1A1MAPTKMT2AKDM4E | |
| SCHEMBL16478691 | 0.81 | JAK3 (0.43) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL12683327 | 0.81 | JAK3 (0.43) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL12424335 | 0.80 | JAK2 (0.38) | MEN1ALDH1A1MAPTKMT2AKDM4E | |
| SCHEMBL16478729 | 0.80 | JAK1 (0.35) | IRAK4MEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987268-B2 | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140011800-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011800-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | JAK3, JAK1, JAK2 | IRAK4 27/4885MEN1 3601/4885ALDH1A1 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.